# Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

> **NCT02107755** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Liver Metastases
- Lung Metastases
- Recurrent Melanoma
- Stage IV Melanoma
- Tumors Metastatic to Brain

## Interventions

- **BIOLOGICAL:** ipilimumab
- **RADIATION:** stereotactic radiosurgery
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02107755
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-05
- **Primary completion:** 2020-08-03
- **Final completion:** 2021-08-16
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02107755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02107755, "Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02107755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*